GlassScriptPhysician profile
William B Minteer
NPI 1184186421
$2,844.52
in general payments reported to CMS, 2019-2025
19 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.95 · 2023: $1,163 · 2024: $390 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024 · Honoraria: $740 · Education: $67.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,023.58 |
| Honoraria | $740.00 |
| Education | $67.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu A/S | $740.00 | 2023 | |
| Cook Medical LLC | $589.76 | 2023-2025 | Hemospray |
| Boston Scientific Corporation | $186.66 | 2022-2025 | Axios, Resolution 360 Ultra Clip, General - Biliary Devices |
| Abbvie INC. | $184.74 | 2023-2025 | |
| Janssen Biotech, INC. | $180.00 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $161.21 | 2025 | Dupixent |
| Madrigal Pharmaceuticals | $138.98 | 2024-2025 | Rezdiffra |
| Pfizer INC. | $130.44 | 2025 | |
| Novo Nordisk INC | $121.37 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $115.45 | 2023 | Zeposia |
| Gilead Sciences, INC. | $57.78 | 2024 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $51.21 | 2023-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $44.69 | 2025 | Voquezna |
| Genzyme Corporation | $38.06 | 2025 | |
| Intercept Pharmaceuticals, INC. | $29.64 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $29.56 | 2023 | Givlaari |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.46 | 2025 | Xifaxan |
| Evoke Pharma, INC. | $14.63 | 2025 | |
| Celltrion USA INC. | $13.88 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Minteer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.